Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper
References
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney international. 2018;94(3):567–81. DOI: 10.1016/j.kint.2018.04.011
- Mensah GA, Fuster V, Roth GA. A heart-healthy and stroke-free world. Journal of the American College of Cardiology. 2023;82(25):2343–9. DOI: 10.1016/j.jacc.2023.11.003
- Institute for Health Metrics and Evaluation. Kidney dysfunction—Level 2 risk 2020.
https://www.healthdata.org/results/gbd_summaries/2019/kidney-dysfunction-level-2-risk . - Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33. DOI: 10.1016/S0140-6736(20)30045-3
- Tuttle KR, Wong L, St Peter W, Roberts G, Rangaswami J, Mottl A, et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol. 2022;17(7):1092–103. DOI: 10.2215/CJN.02980322
- Luyckx VA, Elmaghrabi A, Sahay M, Scholes-Robertson N, Sola L, Speare T, et al. Equity and quality of global CKD Care – what are we waiting for? American Journal of Nephrology. 2024;55(3):298–315. DOI: 10.1159/000535864
- Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney International. 2019;96(5):1048–50. DOI: 10.1016/j.kint.2019.07.012
- Htay H, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, et al. Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney International. 2018;8(2):64–73. DOI: 10.1016/j.kisu.2017.10.010
- Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–22d. DOI: 10.2471/BLT.17.206441
- Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90. DOI: 10.1016/S0140-6736(18)31694-5
- Bikbov B. Core global metrics of chronic kidney disease (CKD) mortality in the GBD 2019 Study. 2023.
https://zenodo.org/records/8312881 . - Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–35. DOI: 10.1161/CIR.0000000000001184
- Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: An individual-participant data meta-analysis. Jama. 2023;330(13):1266–77. DOI: 10.1001/jama.2023.17002
- Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. The Lancet Global Health. 2019;7(10):e1332–e45.
- Ortiz A, Wanner C, Gansevoort R. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Eur J Prev Cardiol. 2022;29(17):2211–5. DOI: 10.1093/eurjpc/zwac186
- Khan MS, Ahmed A, Greene SJ, Fiuzat M, Kittleson MM, Butler J, et al. Managing heart failure in patients on dialysis: State-of-the-Art review. J Card Fail. 2023;29(1):87–107. DOI: 10.1016/j.cardfail.2022.09.013
- Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: A review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11):2017–32. DOI: 10.1093/cvr/cvad083
- Rangaswami J, Shlipak MG, Mathew RO, Ndumele CE. The cardiovascular-kidney-metabolic health framework: Implications for nephrology. Clin J Am Soc Nephrol. 2025. DOI: 10.2215/CJN.0000000744
- Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607–25. DOI: 10.1038/s41581-018-0052-0
- Liu KD, Goldstein SL, Vijayan A, Parikh CR, Kashani K, Okusa MD, et al. AKI!Now initiative: Recommendations for awareness, recognition, and management of AKI. Clin J Am Soc Nephrol. 2020;15(12):1838–47. DOI: 10.2215/CJN.15611219
- Ronco C, Bellasi A, Di Lullo L. Implication of acute kidney injury in heart failure. Heart Fail Clin. 2019;15(4):463–76. DOI: 10.1016/j.hfc.2019.05.002
- Shroff GR, Benjamin MM, Rangaswami J, Lentine KL. Risk and management of cardiac disease in kidney and liver transplant recipients. Heart. 2025. heartjnl-2024-324796. DOI: 10.1136/heartjnl-2024-324796
- Zoccali C, Mark PB, Sarafidis P, Agarwal R, Adamczak M, Bueno de Oliveira R, et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2023;19(11):733–46. DOI: 10.1038/s41581-023-00747-4
- Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72. DOI: 10.1161/CIRCULATIONAHA.120.050686
- Genovesi S, Camm AJ, Covic A, Burlacu A, Meijers B, Franssen C, et al. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation. Nephrol Dial Transplant. 2024;39(8):1248–57. DOI: 10.1093/ndt/gfae121
- Luyckx VA, Elmaghrabi A, Sahay M, Scholes-Robertson N, Sola L, Speare T, et al. Equity and quality of global chronic kidney disease care: What are we waiting for? Am J Nephrol. 2024;55(3):298–315.
- Yarandi N, Shirali AC. Onco-nephrology: Kidney disease in the cancer patient. Med Clin North Am. 2023;107(4):749–62. DOI: 10.1016/j.mcna.2023.03.007
- Dines V, Suvakov S, Kattah A, Vermunt J, Narang K, Jayachandran M, et al. Preeclampsia and the kidney: Pathophysiology and clinical implications. Compr Physiol. 2023;13(1):4231–67. DOI: 10.1002/j.2040-4603.2023.tb00249.x
- Global Coalition for Circulatory Health. Driving sustainable action for circulatory health. White Paper on Circulatory Health. Geneva, Switzerland; 2018.
- Cheong JLY, Olsen JE, Konstan T, Mainzer RM, Hickey LM, Spittle AJ, et al. Growth from infancy to adulthood and associations with cardiometabolic health in individuals born extremely preterm. Lancet Reg Health West Pac. 2023;34:100717. DOI: 10.1016/j.lanwpc.2023.100717
- Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, et al. Kidney outcomes in transthyretin amyloid cardiomyopathy. JAMA Cardiol. 2025;10(1):50–8. DOI: 10.1001/jamacardio.2024.4578
- Zoghbi WA, Duncan T, Antman E, Barbosa M, Champagne B, Chen D, et al. Sustainable development goals and the future of cardiovascular health: A statement from the Global Cardiovascular Disease Taskforce. J Am Coll Cardiol. 2014;64(13):1385–7. DOI: 10.1016/j.jacc.2014.08.018
- Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. Journal of the American Society of Nephrology: JASN. 2007;18(4):1307–15. DOI: 10.1681/ASN.2006101159
- Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73(21):2691–700. DOI: 10.1016/j.jacc.2019.02.071
- Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J. 2014;35(7):455–69. DOI: 10.1093/eurheartj/eht386
- Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2021;78(4):330–43. DOI: 10.1016/j.jacc.2021.05.002
- Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, et al. Heart failure with preserved and reduced ejection fraction in hemodialysis patients: Prevalence, disease prediction and prognosis. Kidney & Blood Pressure Research. 2017;42(1):165–76. DOI: 10.1159/000473868
- Zoccali C, Bolignano D, Mallamaci F.
Left ventricular hypertrophy in chronic kidney disease . In: Goldsmith DJ, Turner NN, Turner NN, Lameire N, Goldsmith DJ, Winearls CG, et al., editors. Oxford Textbook of Clinical Nephrology: Three-Volume Pack. Oxford University Press; 2015. DOI: 10.1093/med/9780199592548.003.0107 - Ulasi, II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation. Ethnicity & Disease. 2006;16(4):859–64.
- Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: The atherosclerosis risk in communities (ARIC) Study. Am Heart J. 2006;151(2):492–500. DOI: 10.1016/j.ahj.2005.03.055
- Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME, et al. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. European journal of preventive cardiology. 2023;30(1):8–16. DOI: 10.1093/eurjpc/zwac176
- Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet. 2012;380(9844):807–14. DOI: 10.1016/S0140-6736(12)60572-8
- Ortiz A, Wanner C, Gansevoort R. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Clinical Kidney Journal. 2023;16(3):403–7. DOI: 10.1093/ckj/sfac199
- Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J. 2004;147(4):623–9. DOI: 10.1016/j.ahj.2003.12.010
- Poulikakos D, Hnatkova K, Skampardoni S, Green D, Kalra P, Malik M. Sudden cardiac death in dialysis: Arrhythmic mechanisms and the value of non-invasive electrophysiology. Frontiers in Physiology. 2019;10:144. DOI: 10.3389/fphys.2019.00144
- Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. DOI: 10.1016/S0140-6736(13)60595-4
- Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis patients: An in-depth review. American Journal of Kidney Diseases. 2011;57(6):921–9. DOI: 10.1053/j.ajkd.2011.02.376
- Marwick TH, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic kidney disease and valvular heart disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney International. 2019;96(4):836–49. DOI: 10.1016/j.kint.2019.06.025
- Bentata Y. Physiopathological approach to infective endocarditis in chronic hemodialysis patients: Left heart versus right heart involvement. Renal Failure. 2017;39(1):432–9. DOI: 10.1080/0886022X.2017.1305410
- Elderia A, Kiehn E, Djordjevic I, Gerfer S, Eghbalzadeh K, Gaisendrees C, et al. Impact of chronic kidney disease and dialysis on outcome after surgery for infective endocarditis. Journal of Clinical Medicine. 2023;12(18). DOI: 10.3390/jcm12185948
- Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The atherosclerosis risk in communities (ARIC) study. Circulation. 2011;123(25):2946–53. DOI: 10.1161/CIRCULATIONAHA.111.020982
- Benn M. Atrial fibrillation and chronic kidney disease. Eur Heart J. 2021;42(29):2824–6. DOI: 10.1093/eurheartj/ehab301
- Park S, Lee S, Kim Y, Lee Y, Kang MW, Kim K, et al. Atrial fibrillation and kidney function: A bidirectional Mendelian randomization study. Eur Heart J. 2021;42(29):2816–23. DOI: 10.1093/eurheartj/ehab291
- Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC study. Kidney International. 2003;64(2):610–5. DOI: 10.1046/j.1523-1755.2003.00109.x
- Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, et al. Chronic kidney disease and cerebrovascular disease: Consensus and guidance from a KDIGO controversies conference. Stroke. 2021;52(7):e328–e46. DOI: 10.1161/STROKEAHA.120.029680
- Muntner P, Judd SE, McClellan W, Meschia JF, Warnock DG, Howard VJ. Incidence of stroke symptoms among adults with chronic kidney disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Nephrology, Dialysis, Transplantation. 2012;27(1):166–73. DOI: 10.1093/ndt/gfr218
- Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: A systematic review and meta-analysis. Nephrology, Dialysis, Transplantation. 2015;30(7):1162–9. DOI: 10.1093/ndt/gfv009
- Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in communities (ARIC) study. Journal of the American Society of Nephrology: JASN. 2007;18(2):629–36. DOI: 10.1681/ASN.2005111204
- Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: A collaborative meta-analysis of individual participant data. The Lancet Diabetes & Endocrinology. 2017;5(9):718–28. DOI: 10.1016/S2213-8587(17)30183-3
- Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney International. 2015;88(5):950–7. DOI: 10.1038/ki.2015.230
- Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One. 2016;11(7):
e0158765 . DOI: 10.1371/journal.pone.0158765 - Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Freedman B, Hindricks G, Banerjee A, Baranchuk A, Ching CK, Du X, et al. World Heart Federation Roadmap on atrial fibrillation – A 2020 update. Glob Heart. 2021;16(1):41. DOI: 10.5334/gh.1023
- Ostrominski JW, Arnold SV, Butler J, Fonarow GC, Hirsch JS, Palli SR, et al. Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999–2020. JAMA Cardiol. 2023;8(11):1050–60. DOI: 10.1001/jamacardio.2023.3241
- Crews DC, Bello AK, Saadi G. Burden, access, and disparities in kidney disease. Brazilian Journal of Medical and Biological Research. 2019;52(3):
e8338 . DOI: 10.1590/1414-431x20198338 - Chesnaye NC, Carrero JJ, Hecking M, Jager KJ. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nature Reviews Nephrology. 2024;20(1):7–20. DOI: 10.1038/s41581-023-00784-z
- Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: Reducing the global burden by 2030. The Lancet. 2021;397(10292):2385–438. DOI: 10.1016/S0140-6736(21)00684-X
- Toth-Manikowski SM, Yang W, Appel L, Chen J, Deo R, Frydrych A, et al. Sex differences in cardiovascular outcomes in CKD: Findings from the CRIC study. American Journal of Kidney Diseases. 2021;78(2):200–9.e1. DOI: 10.1053/j.ajkd.2021.01.020
- Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, et al. Cardiovascular phenotypes in children with CKD: The 4C study. Clinical Journal of the American Society of Nephrology: CJASN. 2017;12(1):19–28. DOI: 10.2215/CJN.01090216
- Jiang D, Wang Q, Shi Z, Sun J. Congenital anomalies of the kidney and urinary tract in children with congenital heart defects. Kidney & Blood Pressure Research. 2020;45(2):307–13. DOI: 10.1159/000504224
- San Agustin JT, Klena N, Granath K, Panigrahy A, Stewart E, Devine W, et al. Genetic link between renal birth defects and congenital heart disease. Nature Communications. 2016;7:11103. DOI: 10.1038/ncomms11103
- Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al.
Hypertension in pregnancy: Diagnosis, blood pressure goals, and pharmacotherapy: A scientific statement from the American Heart Association . Hypertension (Dallas, Tex: 1979). 2022;79(2):e21–e41. DOI: 10.1161/HYP.0000000000000208 - Khan B, Allah Yar R, Khakwani AK, Karim S, Arslan Ali H. Preeclampsia incidence and its maternal and neonatal outcomes with associated risk factors. Cureus. 2022;14(11):
e31143 . DOI: 10.7759/cureus.31143 - Barrett PM, McCarthy FP, Kublickiene K, Cormican S, Judge C, Evans M, et al. Adverse pregnancy outcomes and long-term maternal kidney disease: A systematic review and meta-analysis. JAMA Network Open. 2020;3(2):
e1920964 . DOI: 10.1001/jamanetworkopen.2019.20964 - Crump C, Sundquist J, Sundquist K. Adverse pregnancy outcomes and long-term risk of chronic kidney disease in women: National cohort and co-sibling study. American Journal of Obstetrics and Gynecology. 2023;230(5):563.e1–563.e20. DOI: 10.1136/bmj-2022-072112
- Ekrikpo UE, Adejumo OA, Akpan EE, Udo AI, Nelson U-AU, Umoh IO, et al. The prevalence of acute kidney injury in women with hypertensive disorders of pregnancy in Africa: A systematic review and meta-analysis. African Journal of Nephrology. 2023;26(1):95–105.
- Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circulation Cardiovascular Quality and Outcomes. 2017;10(2). DOI: 10.1161/CIRCOUTCOMES.116.003497
- Institute for Health Metrics and Evaluation. GBD Compare 2019.
https://vizhub.healthdata.org/gbd-compare/ . - Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World Journal of Nephrology. 2014;3(4):143–55. DOI: 10.5527/wjn.v3.i4.143
- Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrology, Dialysis, Transplantation. 1999;14(4):828–33. DOI: 10.1093/ndt/14.4.828
- Barker DJ. The origins of the developmental origins theory. Journal of Internal Medicine. 2007;261(5):412–7. DOI: 10.1111/j.1365-2796.2007.01809.x
- Luyckx VA, Bertram JF, Brenner BM, Fall C, Hoy WE, Ozanne SE, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet. 2013;382(9888):273–83. DOI: 10.1016/S0140-6736(13)60311-6
- Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? American Journal of Hypertension. 1988;1(4 Pt 1):335–47. DOI: 10.1093/ajh/1.4.335
- Crump C. An overview of adult health outcomes after preterm birth. Early Human Development. 2020;150:105187. DOI: 10.1016/j.earlhumdev.2020.105187
- Gjerde A, Lillås BS, Marti HP, Reisæter AV, Vikse BE. Intrauterine growth restriction, preterm birth and risk of end-stage renal disease during the first 50 years of life. Nephrology, Dialysis, Transplantation. 2020;35(7):1157–63. DOI: 10.1093/ndt/gfaa001
- Lawn JE, Ohuma EO, Bradley E, Idueta LS, Hazel E, Okwaraji YB, et al. Small babies, big risks: Global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. Lancet. 2023;401(10389):1707–19. DOI: 10.1016/S0140-6736(23)00522-6
- Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in developed countries. Kidney Int Rep. 2020;5(3):263–77. DOI: 10.1016/j.ekir.2019.12.003
- Perak AM, Ning H, Khan SS, Bundy JD, Allen NB, Lewis CE, et al. Associations of late adolescent or young adult cardiovascular health with premature cardiovascular disease and mortality. J Am Coll Cardiol. 2020;76(23):2695–707. DOI: 10.1016/j.jacc.2020.10.002
- Vasan RS, Zachariah JP, Xanthakis V. Life course developmental approach to cardiovascular health and cardiovascular disease prevention: Opportunities and unanswered questions. J Am Coll Cardiol. 2020;76(23):2708–11. DOI: 10.1016/j.jacc.2020.10.011
- Gooding HC, Gidding SS, Moran AE, Redmond N, Allen NB, Bacha F, et al. Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: Report From a National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association. 2020;9(19):
e016115 . DOI: 10.1161/JAHA.120.016115 - Horesh A, Tsur AM, Bardugo A, Twig G. Adolescent and childhood obesity and excess morbidity and mortality in young adulthood – A systematic review. Curr Obes Rep. 2021;10(3):301–10. DOI: 10.1007/s13679-021-00439-9
- Tsur AM, Akavian I, Landau R, Derazne E, Tzur D, Vivante A, et al. Adolescent body mass index and early chronic kidney disease in young adulthood. JAMA Pediatr. 2024;178(2):142–50. DOI: 10.1001/jamapediatrics.2023.5420
- Tsur AM, Akavian I, Derazne E, Tzur D, Vivante A, Grossman E, et al. Adolescent blood pressure and the risk for early kidney damage in young adulthood. Hypertension. 2022;79(5):974–83. DOI: 10.1161/HYPERTENSIONAHA.121.18748
- Gooding HC, Gidding SS, Moran AE, Redmond N, Allen NB, Bacha F, et al. Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: Report from a National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc. 2020;9(19):
e016115 . DOI: 10.1161/JAHA.120.016115 - Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018;1(7):
e184852 . DOI: 10.1001/jamanetworkopen.2018.4852 - Roomaney RA, van Wyk B, Cois A, Pillay-van Wyk V. One in five South Africans are multimorbid: An analysis of the 2016 demographic and health survey. PLoS One. 2022;17(5):
e0269081 . DOI: 10.1371/journal.pone.0269081 - Gerhardt T, Gerhardt LMS, Ouwerkerk W, Roth GA, Dickstein K, Collins SP, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): A prospective, multicentre, global cohort study. The Lancet Global Health. 2023;11(12):e1874–e84. DOI: 10.1016/S2214-109X(23)00408-4
- Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis. Lancet. 2012;380(9854):1649–61. DOI: 10.1016/S0140-6736(12)61272-0
- Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet. 2012;380(9854):1662–73. DOI: 10.1016/S0140-6736(12)61350-6
- Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. Journal of the American Society of Nephrology. JASN. 2006;17(7):2034–47. DOI: 10.1681/ASN.2005101085
- Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney International Supplement. 2005(99):S25–9. DOI: 10.1111/j.1523-1755.2005.09906.x
- Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. Journal of the American Society of Nephrology. JASN. 1999;10(7):1606–15. DOI: 10.1681/ASN.V1071606
- Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116(1):85–97. DOI: 10.1161/CIRCULATIONAHA.106.678342
- Mikami R, Mizutani K, Gohda T, Matsuyama Y, Gotoh H, Nakagawa K, et al. Malnutrition –inflammation – atherosclerosis (MIA) syndrome associates with periodontitis in end-stage renal disease patients undergoing hemodialysis: A cross-sectional study. Scientific Reports. 2023;13(1):11805. DOI: 10.1038/s41598-023-38959-0
- Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Current Problems in Cardiology. 2024;49(2):102344. DOI: 10.1016/j.cpcardiol.2023.102344
- Yu Z, Grams ME, Ndumele CE, Wagenknecht L, Boerwinkle E, North KE, et al. Association between midlife obesity and kidney function trajectories: The atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2021;77(3):376–85. DOI: 10.1053/j.ajkd.2020.07.025
- Shah PP, Brady TM, Meyers KEC, O’Shaughnessy MM, Gibson KL, Srivastava T, et al. Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. Nephron. 2021;145(3):245–55. DOI: 10.1159/000513869
- Zeitler EM, Glenn DA, Hu Y, Falk RJ, Hogan SL, Mottl AK. Association of obesity with kidney and cardiac outcomes among patients with glomerular disease: Findings from the cure glomerulonephropathy network. Am J Kidney Dis. 2024;84(3):306–19.e1. DOI: 10.1053/j.ajkd.2024.03.020
- Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. DOI: 10.1161/CIR.0000000000000973
- Friedman AN, Wahed AS, Wang J, Courcoulas AP, Dakin G, Hinojosa MW, et al. Effect of bariatric surgery on ckd risk. J Am Soc Nephrol. 2018;29(4):1289–300. DOI: 10.1681/ASN.2017060707
- Mittal B. Subcutaneous adipose tissue & visceral adipose tissue. The Indian Journal of Medical Research. 2019;149(5):571–3. DOI: 10.4103/ijmr.IJMR_1910_18
- Liu J, Fox CS, Hickson DA, May WD, Hairston KG, Carr JJ, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: The Jackson Heart Study. The Journal of Clinical Endocrinology and Metabolism. 2010;95(12):5419–26. DOI: 10.1210/jc.2010-1378
- Rønn PF, Andersen GS, Lauritzen T, Christensen DL, Aadahl M, Carstensen B, et al. Abdominal visceral and subcutaneous adipose tissue and associations with cardiometabolic risk in Inuit, Africans and Europeans: A cross-sectional study. BMJ Open. 2020;10(9):
e038071 . DOI: 10.1136/bmjopen-2020-038071 - Young JA, Hwang SJ, Sarnak MJ, Hoffmann U, Massaro JM, Levy D, et al. Association of visceral and subcutaneous adiposity with kidney function. Clinical journal of the American Society of Nephrology. CJASN. 2008;3(6):1786–91. DOI: 10.2215/CJN.02490508
- Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation. 2001;16(12):2386–94. DOI: 10.1093/ndt/16.12.2386
- Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, et al. Obesity paradox in end-stage kidney disease patients. Progress in Cardiovascular Diseases. 2014;56(4):415–25. DOI: 10.1016/j.pcad.2013.10.005
- United Nations. The 17 Goals; 2015.
https://sdgs.un.org/goals . - Luyckx VA. Equity is key to build back better after COVID-19: Prioritize noncommunicable diseases and kidney health. Kidney360. 2021;2(4):747–50. DOI: 10.34067/KID.0006932020
- Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, et al. Social determinants of cardiovascular disease. Circulation Research. 2022;130(5):782–99. DOI: 10.1161/CIRCRESAHA.121.319811
- Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic status and cardiovascular outcomes: Challenges and interventions. Circulation. 2018;137(20):2166–78. DOI: 10.1161/CIRCULATIONAHA.117.029652
- Crews DC, Hall YN. Social disadvantage: perpetual origin of kidney disease. Advances in Chronic Kidney Disease. 2015;22(1):4–5. DOI: 10.1053/j.ackd.2014.11.003
- Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association. Circulation. 2020;142(17):e265–e86. DOI: 10.1161/CIR.0000000000000935
- Rangaswami J, Mathew RO. Mitigating cardiovascular disease risk in patients with type 2 diabetes and chronic kidney disease-an unmet need with promising solutions. JAMA Cardiol. 2023;8(8):742–3. DOI: 10.1001/jamacardio.2023.1512
- Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD registry. JAMA Network Open. 2019;2(12):e1918169–e. DOI: 10.1001/jamanetworkopen.2019.18169
- Luyckx VA, Tuttle KR, Abdellatif D, Correa-Rotter R, Fung WWS, Haris A, et al. Mind the gap in kidney care: Translating what we know into what we do. Kidney International. 2024;105(3):406–17. DOI: 10.1016/j.kint.2023.12.003
- Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019;394(10199):652–62. DOI: 10.1016/S0140-6736(19)30955-9
- Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: An analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639–51. DOI: 10.1016/S0140-6736(19)31145-6
- Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, et al. Improving health outcomes of people with diabetes: Target setting for the WHO Global Diabetes Compact. Lancet. 2023;401(10384):1302–12. DOI: 10.1016/S0140-6736(23)00001-6
- Kist JM, Vos RC, Mairuhu ATA, Struijs JN, van Peet PG, Vos HMM, et al. SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: An external validation study. EClinicalMedicine. 2023;57:101862. DOI: 10.1016/j.eclinm.2023.101862
- Larkin H. What to know about PREVENT, the AHA’s new cardiovascular disease risk calculator. Jama. 2024;331(4):277–9. DOI: 10.1001/jama.2023.25115
- Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation. 2023;148(24):1982–2004. DOI: 10.1161/CIR.0000000000001191
- Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2013;3(1).
https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf . - Jarraya F, Niang A, Bagha H, Tannor EK, Sumaili EK, Wan DIM, et al. The role of sodium-glucose cotransporter-2 inhibitors in the treatment paradigm of CKD in Africa: An African Association of Nephrology Panel position paper. Kidney International Reports. 2024;9(3):526–48. DOI: 10.1016/j.ekir.2023.12.019
- Luyckx VA, Anandh U. Transporting Sodium-Glucose Cotransporter-2 Inhibitors to the African continent: Challenges and solutions. Kidney International Reports. 2024;9(3):516–9. DOI: 10.1016/j.ekir.2023.11.029
- Ashuntantang G, Osafo C, Olowu WA, Arogundade F, Niang A, Porter J, et al. Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: A systematic review. The Lancet Global Health. 2017;5(4):e408–e17. DOI: 10.1016/S2214-109X(17)30057-8
- CKD Workgroup. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4s):S117–S314. DOI: 10.1016/j.kint.2023.10.018
- MacKinnon HJ, Wilkinson TJ, Clarke AL, Gould DW, O’Sullivan TF, Xenophontos S, et al. The association of physical function and physical activity with all-cause mortality and adverse clinical outcomes in nondialysis chronic kidney disease: A systematic review. Therapeutic Advances in Chronic Disease. 2018;9(11):209–26. DOI: 10.1177/2040622318785575
- Mallamaci F, D’Arrigo G, Tripepi G, Lamberti N, Torino C, Manfredini F, et al. Long-term effect of physical exercise on the risk for hospitalization and death in dialysis patients: A post-trial long-term observational study. Clinical Journal of the American Society of Nephrology: CJASN. 2022;17(8):1176–82. DOI: 10.2215/CJN.03160322
- He L, Biddle SJH, Lee JT, Duolikun N, Zhang L, Wang Z, et al. The prevalence of multimorbidity and its association with physical activity and sleep duration in middle aged and elderly adults: A longitudinal analysis from China. The International Journal of Behavioral Nutrition and Physical Activity. 2021;18(1):77. DOI: 10.1186/s12966-021-01150-7
- Kelly JT, Su G, Zhang L, Qin X, Marshall S, González-Ortiz A, et al. Modifiable lifestyle factors for primary prevention of CKD: A systematic review and meta-analysis. Journal of the American Society of Nephrology: JASN. 2021;32(1):239–53. DOI: 10.1681/ASN.2020030384
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484
- Luyckx VA, Al-Aly Z, Bello AK, Bellorin-Font E, Carlini RG, Fabian J, et al. Sustainable development goals relevant to kidney health: An update on progress. Nature Reviews Nephrology. 2021;17(1):15–32. DOI: 10.1038/s41581-020-00363-6
- Norton JM, Moxey-Mims MM, Eggers PW, Narva AS, Star RA, Kimmel PL, et al. Social determinants of racial disparities in CKD. Journal of the American Society of Nephrology: JASN. 2016;27(9):2576–95. DOI: 10.1681/ASN.2016010027
- Taylor DM, Fraser SDS, Bradley JA, Bradley C, Draper H, Metcalfe W, et al. A systematic review of the prevalence and associations of limited health literacy in CKD. Clinical Journal of the American Society of Nephrology: CJASN. 2017;12(7):1070–84. DOI: 10.2215/CJN.12921216
- Jiamjariyapon T, Ingsathit A, Pongpirul K, Vipattawat K, Kanchanakorn S, Saetie A, et al. Effectiveness of integrated care on delaying progression of stage 3–4 chronic kidney disease in rural communities of Thailand (ESCORT study): A cluster randomized controlled trial. BMC Nephrology. 2017;18(1):83. DOI: 10.1186/s12882-016-0414-4
- Magnani JW, Ning H, Wilkins JT, Lloyd-Jones DM, Allen NB. Educational attainment and lifetime risk of cardiovascular disease. JAMA Cardiol. 2024;9(1):45–54. DOI: 10.1001/jamacardio.2023.3990
- Jafar TH, Gandhi M, de Silva HA, Jehan I, Naheed A, Finkelstein EA, et al. A community-based intervention for managing hypertension in rural South Asia. N Engl J Med. 2020;382(8):717–26. DOI: 10.1056/NEJMoa1911965
- Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International. 2005(99):S57–65. DOI: 10.1111/j.1523-1755.2005.09911.x
- Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: Cardiorenal effects and implications for renal and cardiovascular disease states. The American Journal of the Medical Sciences. 2003;326(1):15–24. DOI: 10.1097/00000441-200307000-00003
- KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. 2022;102(5s):S1–S127. DOI: 10.1016/j.kint.2022.06.008
- Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-Glucose Cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative meta-analysis. Circulation. 2024;149(23):1789–801. DOI: 10.1161/CIRCULATIONAHA.124.069568
- Baigent C, Anker SD, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801. DOI: 10.1016/S0140-6736(22)02074-8
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21. DOI: 10.1056/NEJMoa2403347
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–84. DOI: 10.1093/eurheartj/ehab777
- Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. European Journal of Pharmacology. 2020;884:173444. DOI: 10.1016/j.ejphar.2020.173444
- International Society of Nephrology. Optimization of RAASi Therapy Toolkit; 2024
https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ . - Beldhuis IE, Lam CSP, Testani JM, Voors AA, Spall HGCV, Maaten JMt, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145(9):693–712. DOI: 10.1161/CIRCULATIONAHA.121.052792
- Ozawa S, Shankar R, Leopold C, Orubu S. Access to medicines through health systems in low- and middle-income countries. Health Policy and Planning. 2019;34(Supplement_3):iii1–iii3. DOI: 10.1093/heapol/czz119
- Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocrine Disorders. 2022;22(1):111. DOI: 10.1186/s12902-022-01026-2
- Kondo T, Wang X, Yang M, Jhund PS, Claggett BL, Vaduganathan M, et al. Efficacy of Dapagliflozin according to geographic location of patients with heart failure. J Am Coll Cardiol. 2023;82(10):1014–26. DOI: 10.1016/j.jacc.2023.05.056
- Francis A, Abdul Hafidz MI, Ekrikpo UE, Chen T, Wijewickrama E, Tannor EK, et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries|. Kidney international. 2022;102(5):969–73. DOI: 10.1016/j.kint.2022.07.029
- López-Jaramillo P, González-Gómez S, Zarate-Bernal D, Serrano A, Atuesta L, Clausen C, et al. Polypill: An affordable strategy for cardiovascular disease prevention in low-medium-income countries. Ther Adv Cardiovasc Dis. 2018;12(6):169–74. DOI: 10.1177/1753944718764588
- Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet. 2016;387(10013):61–9. DOI: 10.1016/S0140-6736(15)00469-9
- Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ global health. 2020;5(11). DOI: 10.1136/bmjgh-2020-002640
- Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: An analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc. 2020;9(9):
e015302 . DOI: 10.1161/JAHA.119.015302 - Jan S, Laba TL, Essue BM, Gheorghe A, Muhunthan J, Engelgau M, et al. Action to address the household economic burden of non-communicable diseases. Lancet. 2018;391(10134):2047–58. DOI: 10.1016/S0140-6736(18)30323-4
- Adeniji FIP, Obembe TA. Cardiovascular disease and its implication for higher catastrophic health expenditures among households in Sub-Saharan Africa. Journal of Health Economics and Outcomes Research. 2023;10(1):59–67. DOI: 10.36469/jkheor.2023.70252
- Dodd R, Palagyi A, Guild L, Jha V, Jan S. The impact of out-of-pocket costs on treatment commencement and adherence in chronic kidney disease: A systematic review. Health Policy and Planning. 2018;33(9):1047–54. DOI: 10.1093/heapol/czy081
- Murphy A, McGowan C, McKee M, Suhrcke M, Hanson K. Coping with healthcare costs for chronic illness in low-income and middle-income countries: A systematic literature review. BMJ Global Health. 2019;4(4):
e001475 . DOI: 10.1136/bmjgh-2019-001475 - Zhao Y, Atun R, Oldenburg B, McPake B, Tang S, Mercer SW, et al. Physical multimorbidity, health service use, and catastrophic health expenditure by socioeconomic groups in China: An analysis of population-based panel data. The Lancet Global Health. 2020;8(6):e840–e9. DOI: 10.1016/S2214-109X(20)30127-3
- Zhao Y, Atun R, Anindya K, McPake B, Marthias T, Pan T, et al. Medical costs and out-of-pocket expenditures associated with multimorbidity in China: Quantile regression analysis. BMJ Global Health. 2021;6(2):
e004042 . DOI: 10.1136/bmjgh-2020-004042 - Roberti J, Cummings A, Myall M, Harvey J, Lippiett K, Hunt K, et al. Work of being an adult patient with chronic kidney disease: A systematic review of qualitative studies. BMJ Open. 2018;8(9):
e023507 . DOI: 10.1136/bmjopen-2018-023507 - Choi S, Jang S-Y, Choi E, Park Ys. Association between prevalence and severity of chronic kidney disease and employment status: a nationwide study in Korea. BMC Public Health. 2024;24(1):216. DOI: 10.1186/s12889-023-17338-4
- Alma MA, van der Mei SF, Brouwer S, Hilbrands LB, van der Boog PJM, Uiterwijk H, et al. Sustained employment, work disability and work functioning in CKD patients: A cross-sectional survey study. Journal of Nephrology. 2023;36(3):731–43. DOI: 10.1007/s40620-022-01476-w
- Hallab A, Wish JB. Employment among Patients on Dialysis: An unfulfilled promise. Clinical Journal of the American Society of Nephrology: CJASN. 2018;13(2):203–4. DOI: 10.2215/CJN.13491217
- Kutner N, Bowles T, Zhang R, Huang Y, Pastan S. Dialysis facility characteristics and variation in employment rates: a national study. Clinical Journal of the American Society of Nephrology: CJASN. 2008;3(1):111–6. DOI: 10.2215/CJN.02990707
- Helanterä I, Haapio M, Koskinen P, Grönhagen-Riska C, Finne P. Employment of patients receiving maintenance dialysis and after kidney transplant: A cross-sectional study from Finland. American Journal of Kidney Diseases. 2012;59(5):700–6. DOI: 10.1053/j.ajkd.2011.08.025
- Lakshmi BS, Kumar ACV, Reddy HK, Gopal J, Chaitanya V, Chandra VS, et al. Employment status of patients receiving maintenance dialysis – peritoneal and hemodialysis: A cross-sectional study. Indian Journal of Nephrology. 2017;27(5):384–8. DOI: 10.4103/ijn.IJN_151_16
- Erickson KF, Zhao B, Ho V, Winkelmayer WC. Employment among patients starting dialysis in the United States. Clinical Journal of the American Society of Nephrology: CJASN. 2018;13(2):265–73. DOI: 10.2215/CJN.06470617
- Reibis R, Salzwedel A, Abreu A, Corra U, Davos C, Doehner W, et al. The importance of return to work: How to achieve optimal reintegration in ACS patients. European Journal of Preventive Cardiology. 2019;26(13):1358–69. DOI: 10.1177/2047487319839263
- Rørth R, Wong C, Kragholm K, Fosbøl EL, Mogensen UM, Lamberts M, et al. Return to the workforce after first hospitalization for heart failure: A Danish nationwide cohort study. Circulation. 2016;134(14):999–1009. DOI: 10.1161/CIRCULATIONAHA.116.021859
- Smedegaard L, Numé AK, Charlot M, Kragholm K, Gislason G, Hansen PR. Return to work and risk of subsequent detachment from employment after myocardial infarction: Insights from Danish nationwide registries. Journal of the American Heart Association. 2017;6(10). DOI: 10.1161/JAHA.117.006486
- Hagengaard L, Tayal B, Schou M, Gislason G, Riahi S, Torp-Pedersen C, et al. P6587 Return to work and maintenance of work after first time hospitalization for atrial fibrillation or flutter. European Heart Journal. 2018;39(suppl_1). DOI: 10.1093/eurheartj/ehy566.P6587
- Català Tella N, Serna Arnaiz C, Real Gatius J, Yuguero Torres O, Galván Santiago L. Assessment of the length of sick leave in patients with ischemic heart disease. BMC Cardiovascular Disorders. 2017;17(1):32. DOI: 10.1186/s12872-016-0460-7
- D’Oro A, Patel DH, Wass S, Dolber T, Nasir K, Dobre M, et al. Depression and incident cardiovascular disease among patients with chronic kidney disease. International Journal of Cardiology Cardiovascular Risk and Prevention. 2023;18:200199. DOI: 10.1016/j.ijcrp.2023.200199
- Kivimäki M, Pentti J, Ferrie JE, Batty GD, Nyberg ST, Jokela M, et al. Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study. The Lancet Diabetes & Endocrinology. 2018;6(9):705–13. DOI: 10.1016/S2213-8587(18)30140-2
- Qureshi NQ, Mufarrih SH, Bloomfield GS, Tariq W, Almas A, Mokdad AH, et al. Disparities in cardiovascular research output and disease outcomes among high-, middle- and low-income countries – an analysis of global cardiovascular publications over the last decade (2008–2017). Global heart. 2021;16(1):4. DOI: 10.5334/gh.815
- NCD Countdown 2030. Worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4. Lancet. 2018;392(10152):1072–88. DOI: 10.1016/S0140-6736(18)31992-5
- World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020; 2013.
https://www.who.int/publications/i/item/9789241506236 . - World Health Organization. ‘Best buys’ and other recommended interventions for the prevention and control of noncommunicable diseases; 2017.
https://iris.who.int/bitstream/handle/10665/259232/WHO-NMH-NVI-17.9-eng.pdf?sequence=1 . - World Health Organization. Saving lives, spending less: The case for investing in noncommunicable diseases; 2021.
- Allen LN. Financing national non-communicable disease responses. Global Health Action. 2017;10(1):1326687. DOI: 10.1080/16549716.2017.1326687
- Allen LN, Wigley S, Holmer H. Implementation of non-communicable disease policies from 2015 to 2020: A geopolitical analysis of 194 countries. The Lancet Global Health. 2021;9(11):e1528–e38. DOI: 10.1016/S2214-109X(21)00359-4
- Subramanian S, Gakunga R, Kibachio J, Gathecha G, Edwards P, Ogola E, et al. Cost and affordability of non-communicable disease screening, diagnosis and treatment in Kenya: Patient payments in the private and public sectors. PLoS One. 2018;13(1):
e0190113 . DOI: 10.1371/journal.pone.0190113 - Economics DA. Changing the chronic kidney disease landscape: The economic benefits of early detection and treatment; 2023.
- Walbaum M, Scholes S, Rojas R, Mindell JS, Pizzo E. Projection of the health and economic impacts of chronic kidney disease in the Chilean population. PLoS One. 2021;16(9):
e0256680 . DOI: 10.1371/journal.pone.0256680 - Paffett M, Phannajit J, Chavarina KK, Chuanchaiyakul T, Jiamjariyapon T, Thanachayanont T, et al. Economic evaluation of an integrated care program compared to conventional care for patients with chronic kidney disease in rural communities of Thailand. Kidney Int Rep. 2024;9(8):2546–58. DOI: 10.1016/j.ekir.2024.05.012
- Kostova D, Spencer G, Moran AE, Cobb LK, Husain MJ, Datta BK, et al. The cost-effectiveness of hypertension management in low-income and middle-income countries: A review. BMJ Global Health. 2020;5(9). DOI: 10.1136/bmjgh-2019-002213
- Beshah SA, Husain MJ, Dessie GA, Worku A, Negeri MG, Banigbe B, et al. Cost analysis of the WHO-HEARTS program for hypertension control and CVD prevention in primary health facilities in Ethiopia. Public health in practice (Oxford, England). 2023;6:100423. DOI: 10.1016/j.puhip.2023.100423
- Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: Evidence from a systematic literature review. Advances in Therapy. 2021;38(2):994–1010. DOI: 10.1007/s12325-020-01607-4
- Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrology. 2015;16:65. DOI: 10.1186/s12882-015-0054-0
- Foundation BH. UK factsheet 2024; 2024.
- Kidney Research UK. Kidney disease: A UK public health emergency; 2023.
- Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. European Cardiology. 2022;17:
e17 . DOI: 10.15420/ecr.2021.33 - World Health Organization. The WHO Global Diabetes Compact.
https://www.who.int/initiatives/the-who-global-diabetes-compact . - World Health Organization. HEARTS: Technical package for cardiovascular disease management in primary health care: Risk-based CVD management. 2020.
https://www.who.int/publications/i/item/9789240001367 . - Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A Synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–64. DOI: 10.1161/CIR.0000000000001186
- Figueroa JF, Frakt AB, Jha AK. Addressing social determinants of health: Time for a polysocial risk score. Jama. 2020;323(16):1553–4. DOI: 10.1001/jama.2020.2436
- Khurana D, Leung G, Sasaninia B, Tran D, Khan M, Firek A. The whole PERSON health score: A patient-focused tool to measure nonmedical determinants of health. NEJM Catalyst. 2022;3. DOI: 10.1056/CAT.22.0096
DOI: https://doi.org/10.5334/gh.1460 | Journal eISSN: 2211-8179
Language: English
Submitted on: Apr 30, 2025
Accepted on: Aug 7, 2025
Published on: Oct 7, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2025 Jagat Narula, Javed Butler, Yazied Chothia, Debasish Banerjee, Faical Jarraya, Ifeoma Ulasi, Valerie Luyckx, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.